{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:51:09Z","timestamp":1773327069764,"version":"3.50.1"},"reference-count":8,"publisher":"SMC Media","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background: Hypothyroid crisis, or myxoedema coma, is a rare condition with high mortality and must be treated promptly. Even though it may be unfavourable, most guidelines only focus on intravenous drug administration due to lack of data on oral treatment. Methods\/Results: The course of oral treatment in two patients admitted in our hospital is described. Patients were treated with levothyroxine 1.3 \u00b5g\/kg and liothyronine 25 \u00b5g twice daily, followed after 1 week with only levothyroxine 1.3 \u00b5g\/kg daily. Oral treatment was successful in both patients without complications or side-effects. Conclusions: Oral substitution is an appropriate alternative to intravenous substitution, which has potential disadvantages and is associated with higher mortality.<\/jats:p>","DOI":"10.12890\/2021_002752","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T02:50:45Z","timestamp":1631242245000},"source":"Crossref","is-referenced-by-count":3,"title":["Hypothyroid Crisis: Oral or Intravenous Treatment? A Report of Two Cases"],"prefix":"10.12890","volume":"8","author":[{"given":"Rens","family":"Gadaen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Thyroid Centre, Zuyderland Medical Centre, Sittard-Geleen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick","family":"Tummers - de Lind van Wijngaarden","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Thyroid Centre, Zuyderland Medical Centre, Sittard-Geleen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10397","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"10.12890\/2021_002752_ref1","unstructured":"<li>Wall CR. Myxedema coma: diagnosis and treatment. <em>Am Fam Physician<\/em> 2000;<strong>62<\/strong>(11):2485\u20132490. <\/li>"},{"key":"10.12890\/2021_002752_ref2","unstructured":"<li>Het Acute Boekje. Endocrinology, myxedema coma \u2013 hypothyroid crisis. Available at www.hetacuteboekje.nl (accessed 15 June 2020).<\/li>"},{"key":"10.12890\/2021_002752_ref3","doi-asserted-by":"crossref","unstructured":"<li>Popoveniuc G, Chandra T, Sud A, Sharma M, Blackman MR, Burman KD, et al. A diagnostic scoring system for myxedema coma. <em>Endocr Pract<\/em> 2014;<strong>20<\/strong>(8):808\u2013817. doi: 10.4158\/ep13460.or <\/li>","DOI":"10.4158\/EP13460.OR"},{"key":"10.12890\/2021_002752_ref4","doi-asserted-by":"crossref","unstructured":"<li>Arlot S, Debussche X, Lalau JD, Mesmacque A, Tolani M, Quichaud J, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. <em>Intensive Care Med<\/em> 1991;<strong>17<\/strong>(1):16\u201318. doi: 10.1007\/BF01708403<\/li>","DOI":"10.1007\/BF01708403"},{"key":"10.12890\/2021_002752_ref5","doi-asserted-by":"crossref","unstructured":"<li>Charoensri S, Sriphrapradang C, Nimitphong H. Split high-dose oral levothyroxine treatment as a successful therapy option in myxedema coma. <em>Clin Case Rep<\/em> 2017;<strong>5<\/strong>(10):1706\u20131711. doi: 10.1002\/ccr3.1131<\/li>","DOI":"10.1002\/ccr3.1131"},{"key":"10.12890\/2021_002752_ref6","doi-asserted-by":"crossref","unstructured":"<li>Rajendran A, Bhavani N, Nair V, Pavithran PV, Menon VU, Kumar H. Oral levothyroxine is an effective option for myxedema coma: a single-centre experience. <em>Eur Thyroid J<\/em> 2021;<strong>10<\/strong>:52\u201358. doi: 10.1159\/000507855<\/li>","DOI":"10.1159\/000507855"},{"key":"10.12890\/2021_002752_ref7","doi-asserted-by":"crossref","unstructured":"<li>Papi G, Corsello SM, Pontecorvi A. Clinical concepts on thyroid emergencies. <em>Front Endocrinol (Lausanne)<\/em> 2014;<strong>5<\/strong>:102. doi: 10.3389\/fendo.2014.00102<\/li>","DOI":"10.3389\/fendo.2014.00102"},{"key":"10.12890\/2021_002752_ref8","doi-asserted-by":"crossref","unstructured":"<li>Hylander, B, Rosenqvist U. Treatment of myxoedema coma \u2013 factors associated with fatal outcome. <em>Acta Endocrinol (Copenh)<\/em> 1985;<strong>108<\/strong>(1):65\u201371. doi: 10.1530\/acta.0.1080065 <\/li>","DOI":"10.1530\/acta.0.1080065"}],"container-title":["European Journal of Case Reports in Internal Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2752\/2831","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2752\/2832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/download\/2752\/2832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:27:11Z","timestamp":1756128431000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejcrim.com\/index.php\/EJCRIM\/article\/view\/2752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":8,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.12890\/2021_002752","relation":{"has-manifestation":[{"id-type":"other","id":"1-77-2752-g2831","asserted-by":"subject"},{"id-type":"other","id":"1-77-2752-g2832","asserted-by":"subject"}],"is-part-of":[{"id-type":"other","id":"1-77","asserted-by":"subject"}]},"ISSN":["2284-2594"],"issn-type":[{"value":"2284-2594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"8"}}